John Rim, CEO of Samsung Biologics, won a third consecutive term.
Samsung Biologics on the 20th held its 15th annual general shareholders' meeting at Songdo Convensia in Incheon and approved as originally proposed the agenda item to appoint (reappoint) inside director John Rim. The agenda item to reappoint Executive Vice President No Gyun (head of the EPCV Center) also passed, and Professor Kim Jeong-yeon was newly appointed as an outside director and audit committee member.
At the meeting, CEO John Rim said, "We secured a global production base by acquiring the Rockville, U.S., plant," and noted, "We expanded our business domain by launching the Organoid service and focused on broadening the portfolio, including securing a site for the third bio campus to respond to new modalities."
In particular, by acquiring the Rockville plant in the United States and securing the first local production base, about 60,000 liters of additional capacity will be added. As a result, Samsung Biologics' total global capacity is expected to expand to about 845,000 liters, including existing capacity.
On the agenda were five items in total: ▲ approval of financial statements ▲ changes to the articles of incorporation ▲ appointment of inside directors ▲ appointment of outside directors and audit committee members ▲ approval of the limit on directors' remuneration, and all passed as originally proposed.
The meeting was held in a hybrid format with in-person attendance and an online live stream, and about 1,400 shareholders took part. The company supported the exercise of voting rights by conducting electronic voting from the 10th to the 19th.
Meanwhile, Samsung Epis Holdings, the holding company of Samsung Bioepis that held its first shareholders' meeting after the spin-off, tabled six proposals, including approval of the first-term financial statements, appointment of inside directors and audit committee members, and approval of the limit on directors' remuneration, and all passed as originally proposed.
Of 24,830,611 shares with voting rights, 702 holders (21,133,922 shares) attended, recording an attendance rate of 85.1%.
The appointment of Chief Financial Officer (CFO) and Executive Vice President Kim Hyeong-jun as an inside director, the most watched agenda item of the day, also passed without issue. Born in 1966, Executive Vice President Kim had served as a non-registered executive overseeing finance at Samsung Epis Holdings, and with entry to the board, analysts say the role will expand further in key decision-making processes, including financial strategy.
In particular, as the importance of financial decision-making grows amid an expansion phase in new drug development, the CFO's influence on the board is expected to expand structurally.
Executive Vice President Kim joined Samsung Bioepis in 2020 after stints at Samsung Electronics' Mobile Communications Business and Visual Display Business in Mexico, and later served as head of management support. After the Samsung Biologics spin-off, Kim moved to Samsung Epis Holdings and currently serves concurrently as CFO and head of management support at EPIS NexLab.
Samsung Epis Holdings is a bio holding company launched in Nov. 2025, with subsidiaries Samsung Bioepis and EPIS NexLab, a developer of next-generation platform technologies. EPIS NexLab is a small organization specialized in research on peptide-based platform technologies.
CEO Kim Kyung-ah presented a strategy at the meeting to begin in earnest a transition from a biosimilar-centered business to a new drug developer.
Kim said, "While continuing to develop follow-on product lines targeting major biologics with patents set to expire, we are preparing to enter global clinical trials, led by new drug candidates based on antibody-drug conjugates (ADC)."
The plan also calls for expanding joint research and technology transfer opportunities with global pharmaceutical companies, based on platform technologies secured through EPIS NexLab. The technology is cited for its scalability that can be applied to a range of diseases.
Such business expansion is directly tied to financial strategy and aligns with CFO Kim's entry to the board. That is because while the biosimilar business has a relatively stable revenue structure, new drug development entails large upfront investment and high uncertainty.
Going forward, overall capital allocation—including research and development (R&D) expense execution, investments in subsidiaries, and external technology introduction—is expected to emerge as a key decision-making issue, and the CFO's role on the board is likewise expected to grow more important.